Skip to main content
. 2018 Feb 8;17(4):5581–5588. doi: 10.3892/mmr.2018.8580

Figure 2.

Figure 2.

Cell proliferation evaluation using the BrdU assay in the presence of the indicated concentrations of ruxolitinib and/or calcitriol in MCF7-HER18 cells for 72 h. The data are presented as the mean ± standard deviation. *P<0.05. BrdU, bromodeoxyuridine; HER, human epidermal growth factor receptor.